A Nature Biotechnology report described an engineered UGA suppressor tRNA intended to expand AAV‑based protein delivery across disease contexts by enabling readthrough of UGA stop codons. The suppressor tRNA design aims to make AAV payloads more flexible and disease‑agnostic, potentially simplifying vector design for disorders caused by nonsense mutations. Authors presented in vivo proof‑of‑concept data and addressed orthogonality and safety considerations relevant to translational development. The paper frames suppressor tRNAs as a platform tool that could reduce the need for bespoke constructs per disease, but regulators will scrutinize off‑target readthrough and long‑term expression. Clarification: a 'suppressor tRNA' is an engineered transfer RNA that overrides a stop codon to permit synthesis of a full‑length protein from mutant mRNA.